Home › Triple-Negative Breast Cancer › Rhode Island
Triple-Negative Breast Cancer clinical trials in Rhode Island
4 studies for Triple-Negative Breast Cancer are looking for participants at sites in Rhode Island.
Cities in Rhode Island
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Providence Health, Providence
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05633654Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Women and Infants Hospital of Rhode Island, Providence
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Women & Infants Hospital, Providence
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT05902988Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
- Rhode Island and the Miriam Hospitals (Brown University Health), Providence
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 24, 2025 · NCT06974604From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.